The 340B environment has continued to evolve, and this year has been particularly busy as the drug pricing program is targeted and challenged. Covered Entities (CEs) and other professionals are invited to join us for an update on federal and state regulatory and legislative activity along with a discussion on the administrative dispute resolution process, Medicare Advantage payer litigation, and how CEs can continue to maintain a compliant 340B program despite these challenges.

During this webinar, PYA’s Sarah Bowman will discuss key updates to 340B as attendees learn from these objectives:

- Discuss key state and federal legislative activity
- Provide a regulatory update
- Review the status of drug manufacturer restrictions and the Administrative Dispute Resolution process
- Describe Medicare Advantage payer litigation activity
- Discuss HRSA Audit activity and Covered Entity best practices

This webinar is part of PYA’s twice-monthly Healthcare Regulatory Roundup, a popular series during which PYA experts provide practical insights on the latest industry regulatory developments.

If you would like assistance with legislative or regulatory impacts or any matter involving compliance, valuation, or strategy and transactions, our executives are happy to assist.